Tobam Zai Lab LTD Transaction History

Tobam

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 03, 2023	BUY	$30.21 - $48.1 $110,689 - $176,238	3,664 New	3,664 $122,000
Q1 2022 Apr 25, 2022	SELL	$27.77 - $64.4 $36,101 - $83,720	-1,300 Closed	0 $0
Q4 2021 Feb 15, 2022	SELL	$54.9 - $105.21 $4.61 Million - $8.83 Million	-83,900 Reduced 98.47%	1,300 $82,000
Q3 2021 Nov 12, 2021	SELL	$105.0 - $178.37 $2.1 Million - $3.57 Million	-20,000 Reduced 19.01%	85,200 $8.98 Million
Q2 2021 Aug 11, 2021	SELL	$125.11 - $180.0 $2.63 Million - $3.78 Million	-21,000 Reduced 16.64%	105,200 $18.6 Million
Q1 2021 May 11, 2021	BUY	$126.27 - $191.71 $846,009 - $1.28 Million	6,700 Added 5.61%	126,200 $16.8 Million
Q4 2020 Feb 03, 2021	BUY	$81.94 - $135.34 $1.32 Million - $2.18 Million	16,100 Added 15.57%	119,500 $16.2 Million
Q3 2020 Nov 12, 2020	BUY	$73.3 - $89.48 $3.2 Million - $3.9 Million	43,600 Added 72.91%	103,400 $8.6 Million
Q2 2020 Aug 17, 2020	BUY	$48.82 - $82.53 $2.34 Million - $3.95 Million	47,900 Added 402.52%	59,800 $4.91 Million
Q1 2020 May 07, 2020	BUY	$39.1 - $62.9 $465,290 - $748,510	11,900 New	11,900 $613,000

121

46.7M

223K

588K

Ticker ZLAB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 97,908,704
Market Cap $2.43B
Description
Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience primarily in Mainland China and Hong Kong. The company's commercial products include Zejula, a once-daily small-molecule poly polymerase 1/2 inhibitor; Optune, a device that delivers tumor treating fields; NUZYRA f...

Get notified when there are updates to the investment portfolio of Tobam, based on Form 13F filings with the SEC.

Stay updated on Tobam with notifications on news.